S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Apellis Pharmaceuticals (APLS) Earnings Date, Estimates & Call Transcripts

$68.47
+0.88 (+1.30%)
(As of 02/23/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

APLS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

APLS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Apellis Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243($0.79)($0.70)($0.75)
Q2 20243($0.64)($0.55)($0.60)
Q3 20243($0.58)($0.40)($0.47)
Q4 20243($0.51)($0.27)($0.36)
FY 202412($2.52)($1.92)($2.18)
Q1 20251($0.24)($0.24)($0.24)
Q2 20251($0.07)($0.07)($0.07)
Q3 20251$0.23$0.23$0.23
Q4 20251$0.39$0.39$0.39
FY 20254$0.31$0.31$0.31

APLS Earnings Date and Information

Apellis Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Tuesday, February 27th, 2024. Apellis Pharmaceuticals will be holding an earnings conference call on Tuesday, February 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call..

Apellis Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Confirmed)
-------  
11/1/2023Q3 2023($0.88)($1.17)($0.29)($1.17)$99.05 million$110.40 million    
7/31/2023Q2 2023($1.35)($1.02)+$0.33($1.02)$70.38 million$95.00 million    
5/4/2023Q1 2023($1.42)($1.56)($0.14)($1.56)$26.10 million$44.80 million    
2/21/2023Q4 2022($1.45)($1.50)($0.05)($1.50)$24.44 million$22.70 million
11/7/2022Q3 2022($1.48)($1.75)($0.27)($1.75)$19.82 million$22.06 million
8/8/2022Q2 2022($1.43)($1.46)($0.03)($1.46)$17.16 million$16.32 million    
5/4/2022Q1 2022($1.36)($1.42)($0.06)($1.42)$12.81 million$14.38 million    
2/28/2022Q4 2021($1.32)($1.61)($0.29)($1.61)$8.52 million$60.29 million    
11/8/2021Q3 2021($1.73)($2.28)($0.55)($2.28)$2.32 million$5.65 million    
8/8/2021Q2 2021($1.70)($2.72)($1.02)($2.72)$2.26 million$0.62 million    
4/27/2021Q1 2021($1.69)($2.32)($0.63)($2.32)--  
2/24/2021Q4 2020($0.47)$0.93+$1.40$0.93$184.54 million$250.00 million  












Apellis Pharmaceuticals Earnings - Frequently Asked Questions

When is Apellis Pharmaceuticals's earnings date?

Apellis Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Tuesday, February 27th, 2024. Learn more on APLS's earnings history.

How much revenue does Apellis Pharmaceuticals generate each year?

Apellis Pharmaceuticals (NASDAQ:APLS) has a recorded annual revenue of $75.42 million.

How much profit does Apellis Pharmaceuticals generate each year?

Apellis Pharmaceuticals (NASDAQ:APLS) has a recorded net income of -$652.17 million. APLS has generated -$5.25 earnings per share over the last four quarters.

What is Apellis Pharmaceuticals's EPS forecast for next year?

Apellis Pharmaceuticals's earnings are expected to grow from ($4.41) per share to ($1.10) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:APLS) was last updated on 2/24/2024 by MarketBeat.com Staff

From Our Partners